1. For Critical Care Decisions Saving Lives – Preventing Disabilities THE XCYTON SYNDROME EVALUATION SYSTEM
2.
3.
4.
5.
6.
7.
8.
9.
10.
11. Syndrome Signature Specific amplification The amplified product is introduced onto a Syndrome signature Evaluation Protocol Then it undergoes a process called Signature specific Hybridization, Then an enzymatic reaction occurs and a colored spot appears ..
21. LIMIT OF DETECTION OF PATHOGENS IN AES DNA CHIP Organism Sensitivity (organisms/ ml) Cross reactivity observed HSV 50 particles No M.tuberculosis 50 particle No H.influenzae 140 particles No N.meningitidis 115 particles No S.pneumoniae 400 particles No HHV-6 50 particle No T.gondii 50 particle No CMV 250 particles No VZV 4pfu No C.neoformans 50 particles No JC Not determined No
22. PRECISION STUDY Verification Criteria Reference Acceptance Criteria Precision Qualitative 20 data points; one pos for 20 days or duplicates for 10 days. Extraction to detection CLSI EP12-A MM6-A ≥ 95% precision Precision Quantitative 20 data points at 2-3 conc. Within run, between run, between day. Extraction to detection CLSI EP5-A & MM6-A ≥ 95% precision
23.
24.
25.
26.
27. ACURACY STUDY ON POSTMORTEM PROVEN CASES OF CNS DISEASES Sample Diagnosis Post mortem proven No Tested No Positive HSV Encephalitis 4 4 CMV Encephalitis 3 3 VZV Encephalitis 2 2 Toxoplasma Encephalitis 3 3 Tuberculous meningitis 3 3 Normal CSF’s obtained at spinal anesthesia 25 0